

## INDEX

CONTENTS	Page No.
<b>List of Abbreviations and Symbols</b>	i
<b>List of Figures</b>	ii–vi
<b>List of Tables</b>	vii
<b>Preface</b>	viii–ix
<b>CHAPTER-1: INTRODUCTION</b>	
Drug design, discovery and development	1–3
Epilepsy: an overview	3–4
Etiology and classification of epilepsy	4–6
Management of epilepsy	6–8
Various targets of anticonvulsant drugs	9–13
Other treatment strategies (Non–pharmacological interventions)	13–14
<b>CHAPTER-2: LITERATURE REVIEW</b>	
Glutamate receptors and competitive AMPA receptor antagonists	15–18
Non–competitive AMPA receptor antagonists	19–21
Quinazolinones as anticonvulsants	21–28
Quinazoline derivatives in other diseases	28–30
<b>CHAPTER-3: RATIONALE, OBJECTIVE AND PLAN OF WORK</b>	
Rationale and Objective	31–32
Plan of Work	33
<b>CHAPTER-4: EXPERIMENTAL</b>	
EXPERIMENTAL – PART – 1	
Synthesis of <i>N</i> 3 aryl/heteroaryl substituted 2–(2–chlorostyryl)–6,7–dimethoxy–quinazolin–4(3 <i>H</i> )–ones (Series–I)	34–35
Reaction mechanism (Series–I and II)	35–36
Physicochemical characterization (Series–I)	36–40
Spectral characterization and elemental analysis (Series–I)	40–67
Synthesis of <i>N</i> 3 aryl/heteroaryl substituted 2–((benzyloxy and phenylthio) methyl) 6,7–dimethoxyquinazolin–4(3 <i>H</i> )–ones (Series–II)	68–69
Physicochemical characterization (Series–II)	69–70
Spectral characterization and elemental analysis (Series–II)	70–92
EXPERIMENTAL – PART – 2	
Pharmacological Evaluation	93–96
Active site prediction, molecular docking and <i>in silico</i> pharmacokinetic predictions	96–98

<b>CHAPTER-5: RESULTS AND DISCUSSION</b>	
Chemistry (Series I)	99
Pharmacological activity and hepatotoxicity study (Series I)	99-102
Chemistry (Series II)	103-104
Pharmacological activity and hepatotoxicity study (Series II)	104-106
Partition coefficient and <i>in silico</i> ADME prediction of the synthesized compounds (Series I and II)	107-108
Molecular modelling study	108-112
<b>CHAPTER-6: SUMMARY AND CONCLUSION</b>	113-115
<b>CHAPTER-7: REFERENCES</b>	116-128
<b>Appendix</b>	
List of Publications	129-130
Reprints of Published Papers	
Profile of the Candidate	

## LIST OF FIGURES

Fig. No.	Figure Captions	Page No.
1.1	GABA biosynthesis	10
1.2.	Schematic model of an AMPA receptor subunit	12
3.1.	Template of compounds for series-I and series-II	32
4A.1.	General scheme for the synthesis of compounds <b>5a-5l</b>	35
4A.2.	Mechanism of reaction for the synthesis of quinazolin-4(3 <i>H</i> )-ones	36
4A.3.	FT-IR spectrum of 2-(3-(2-chlorophenyl) acrylamido)-4,5dimethoxybenzoic acid ( <b>3</b> )	45
4A.4.	<sup>1</sup> H NMR spectrum of 2-(3-(2-chlorophenyl) acrylamido)-4,5 dimethoxybenzoic acid ( <b>3</b> )	45
4A.5.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-4 <i>H</i> benzo[d][1,3]oxazin-4-one ( <b>4</b> )	46
4A.6.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-4 <i>H</i> -benzo[d][1,3]oxazin-4-one ( <b>4</b> )	46
4A.7.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-phenylquinazolin-4(3 <i>H</i> )-one ( <b>5a</b> )	47
4A.8.	<sup>1</sup> H NMR of 2-(2-chlorostyryl)-6,7-dimethoxy-3- phenylquinazolin-4(3 <i>H</i> )-one ( <b>5a</b> )	47
4A.9.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-phenylquinazolin-4(3 <i>H</i> )-one ( <b>5a</b> )	48
4A.10.	Mass spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-phenylquinazolin-4(3 <i>H</i> )-one ( <b>5a</b> )	48
4A.11.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5b</b> )	49
4A.12.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5b</b> )	49
4A.13.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2,4 -dimethylphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5b</b> )	50
4A.14.	Mass spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5b</b> )	50
4A.15.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3- <i>m</i> -tolylquinazolin-4(3 <i>H</i> )-one ( <b>5c</b> )	51
4A.16.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3- <i>m</i> -tolylquinazolin-4(3 <i>H</i> )-one ( <b>5c</b> )	51
4A.17.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3- <i>m</i> -tolylquinazolin-4(3 <i>H</i> )-one ( <b>5c</b> )	52
4A.18.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-methoxyphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5d</b> )	52
4A.19.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-methoxyphenyl)quinazolin-4(3 <i>H</i> )-one ( <b>5d</b> )	53

4A.20.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-methoxyphenyl)quinazolin-4(3H)-one ( <b>5d</b> )	53
4A.21.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>5e</b> )	54
4A.22.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>5e</b> )	54
4A.23.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>5e</b> )	55
4A.24.	Mass spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>5e</b> )	55
4A.25.	FT-IR spectrum of 2-(2-chlorostyryl)-3-benzyl-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5f</b> )	56
4A.26.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-3-benzyl-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5f</b> )	56
4A.27.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-3-benzyl-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5f</b> )	57
4A.28.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>5g</b> )	57
4A.29.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>5g</b> )	58
4A.30.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>5g</b> )	58
4A.31.	Mass spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>5g</b> )	59
4A.32.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-nitrophenyl)quinazolin-4(3H)-one ( <b>5h</b> )	59
4A.33.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-nitrophenyl)quinazolin-4(3H)-one ( <b>5h</b> )	60
4A.34.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(2-nitrophenyl)quinazolin-4(3H)-one ( <b>5h</b> )	60
4A.35.	FT-IR spectrum of 2-(2-chlorostyryl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5i</b> )	61
4A.36.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5i</b> )	61
4A.37.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5i</b> )	62
4A.38.	Mass spectrum of 2-(2-chlorostyryl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>5i</b> )	62
4A.39.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyrimidin-2-yl)quinazolin-4(3H)-one ( <b>5j</b> )	63
4A.40.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyrimidin-2-yl)quinazolin-4(3H)-one ( <b>5j</b> )	63
4A.41.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyrimidin-2-yl)quinazolin-4(3H)-one ( <b>5j</b> )	64

4A.42.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyridin-4-yl)quinazolin-4(3H)-one ( <b>5k</b> )	64
4A.43.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyridin-4-yl)quinazolin-4(3H)-one ( <b>5k</b> )	65
4A.44.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(pyridin-4-yl)quinazolin-4(3H)-one ( <b>5k</b> )	65
4A.45.	FT-IR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(thiazol-2-yl)quinazolin-4(3H)-one ( <b>5l</b> )	66
4A.46.	<sup>1</sup> H NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(thiazol-2-yl)quinazolin-4(3H)-one ( <b>5l</b> )	66
4A.47.	<sup>13</sup> C NMR spectrum of 2-(2-chlorostyryl)-6,7-dimethoxy-3-(thiazol-2-yl)quinazolin-4(3H)-one ( <b>5l</b> )	67
4B.1.	General scheme for the synthesis of compounds <b>8a-8l</b>	69
4B.2.	FT-IR spectrum of 2-(2-(benzyloxy)acetamido)-4,5-dimethoxybenzoic acid ( <b>4</b> )	75
4B.3.	<sup>1</sup> H NMR spectrum of 2-(2-(benzyloxy)acetamido)-4,5-dimethoxybenzoic acid ( <b>4</b> )	75
4B.4.	IR spectrum of 2-(2-(phenylthio)acetamido)-4,5-dimethoxybenzoic acid ( <b>5</b> )	76
4B.5.	<sup>1</sup> H NMR spectrum of 2-(2-(phenylthio)acetamido)-4,5-dimethoxybenzoic acid ( <b>5</b> )	76
4B.6.	FT-IR spectrum of 2-((benzyloxy) methyl)-6,7-dimethoxy-4H-benzo[d][1,3]oxazin-4-one ( <b>6</b> )	77
4B.7.	<sup>1</sup> H NMR spectrum 2-((benzyloxy) methyl)-6,7-dimethoxy-4H-benzo[d][1,3]oxazin-4-one ( <b>6</b> )	77
4B.8.	FT-IR spectrum of 6,7-dimethoxy-2-((phenylthio) methyl)-4H-benzo[d][1,3]oxazin-4-one ( <b>7</b> )	78
4B.9.	<sup>1</sup> H NMR spectrum of 6,7-dimethoxy-2-((phenylthio) methyl)-4H-benzo[d][1,3]oxazin-4-one ( <b>7</b> )	78
4B.10.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-m-tolylquinazolin-4(3H)-one ( <b>8a</b> )	79
4B.11.	<sup>1</sup> H NMR spectrum 2-((benzyloxy)methyl)-6,7-dimethoxy-3-m-tolylquinazolin-4(3H)-one ( <b>8a</b> )	79
4B.12.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3H)-one ( <b>8b</b> )	80
4B.13.	<sup>1</sup> H NMR spectrum 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3H)-one ( <b>8b</b> )	80
4B.14.	Mass spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(2,4-dimethylphenyl)quinazolin-4(3H)-one ( <b>8b</b> )	81
4B.15.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>8c</b> )	81
4B.16.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>8c</b> )	82

4B.17.	Mass spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(3-methoxyphenyl)quinazolin-4(3H)-one ( <b>8c</b> )	82
4B.18.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(2-methoxyphenyl)quinazolin-4(3H)-one ( <b>8d</b> )	83
4B.19.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(2-methoxyphenyl)quinazolin-4(3H)-one ( <b>8d</b> )	83
4B.20.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(benzyl)quinazolin-4(3H)-one ( <b>8e</b> )	84
4B.21.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(benzyl)quinazolin-4(3H)-one ( <b>8e</b> )	84
4B.22.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>8f</b> )	85
4B.23.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>8f</b> )	85
4B.24.	Mass spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(4-nitrophenyl)quinazolin-4(3H)-one ( <b>8f</b> )	86
4B.25.	FT-IR spectrum of 2-(benzyloxymethyl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>8g</b> )	86
4B.26.	<sup>1</sup> H NMR spectrum of 2-(benzyloxymethyl)-3-(4-bromophenyl)-6,7-dimethoxyquinazolin-4(3H)-one ( <b>8g</b> )	87
4B.27.	FT-IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(pyridin-4-yl)quinazolin-4(3H)-one ( <b>8h</b> )	87
4B.28.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(pyridin-4-yl)quinazolin-4(3H)-one ( <b>8h</b> )	88
4B.29.	FT-IR spectrum of 2-(benzyloxymethyl)-6,7-dimethoxy-3-(pyrimidin-2-yl)quinazolin-4(3H)-one ( <b>8i</b> )	88
4B.30.	<sup>1</sup> H NMR spectrum of 2-(benzyloxymethyl)-6,7-dimethoxy-3-(pyrimidin-2-yl)quinazolin-4(3H)-one ( <b>8i</b> )	89
4B.31.	IR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(thiazol-2-yl)quinazolin-4(3H)-one ( <b>8j</b> )	89
4B.32.	<sup>1</sup> H NMR spectrum of 2-((benzyloxy)methyl)-6,7-dimethoxy-3-(thiazol-2-yl)quinazolin-4(3H)-one ( <b>8j</b> )	90
4B.33.	FT-IR spectrum of 6,7-dimethoxy-3-(4-nitrophenyl)-2-((phenylthio)methyl)quinazolin-4(3H)-one ( <b>8k</b> )	90
4B.34.	<sup>1</sup> H NMR spectrum of 6,7-dimethoxy-3-(4-nitrophenyl)-2-((phenylthio)methyl)quinazolin-4(3H)-one ( <b>8k</b> )	91
4B.35.	FT-IR spectrum 6,7-dimethoxy-3-(3-methoxyphenyl)-2-((phenylthio)methyl)quinazolin-4(3H)-one ( <b>8l</b> )	91
4B.36.	<sup>1</sup> H NMR spectrum of 6,7-dimethoxy-3-(3-methoxyphenyl)-2-((phenylthio)methyl)quinazolin-4(3H)-one ( <b>8l</b> )	92
4C.1.	The centroid of the sitemap_site1 used in the generation of grid	98
5A.1.	Photomicrograph of liver at 40X magnification (a) control, (b) compound 5g, (c) 5i and (d) GYKI 52466 treated groups	102

5B.1.	Photomicrograph of liver at 40X magnification (a) control, (b) 8f, (c) 8h and (d) GYKI 52466 treated groups	106
5C.2.1.	Compound 5g hydrogen bonded with key amino acid residues (Arg 108 and Lys 269)	110
5C.2.2.	Compound 5g docked within the predicted binding pocket of ATD of glutamate receptor	110
5C.2.3.	GYKI 52466 docked within the predicted binding pocket of ATD of glutamate receptor	111
5C.2.4.	Compound 8f docked within the predicted binding pocket of ATD of glutamate receptor	111
5C.2.5.	Compound 8f within the binding cavity formed by loop residues	112

## LIST OF TABLES

Table No.	Table Captions	Page No.
1.1.	Anticonvulsant drugs and their mechanism of action	8
2.1.	Quinazoline derivatives and their biological activities	29–30
4A.1.	List of synthesized compounds and physicochemical data ( <b>5a–5l</b> )	38
4A.2.	Partition coefficient and solubility of synthesized compounds ( <b>5a–5l</b> )	39
4B.1.	List of the synthesized compounds and physicochemical data ( <b>8a–8l</b> )	70
4B.2.	Partition coefficient and solubility of synthesized compounds ( <b>8a–8l</b> )	70
4C.1.	Top-ranked SiteMap® prediction for receptor binding sites	97
4C.2.	Qikprop® properties and descriptors	98
5A.1	Anticonvulsant activity of compounds <b>5a–5l</b> against MES, scPTZ and AMPA induced seizure	101
5A.2.	Effects of compounds ( <b>5g</b> and <b>5i</b> ) on serum AST and ALT of rats	102
5B.1	Anticonvulsant activity of compounds <b>8a–8l</b> against MES, scPTZ and <i>icv</i> AMPA-induced seizure	105
5B.2.	Effects of compounds ( <b>8f</b> and <b>8h</b> ) on serum AST and ALT of rats	106
5C.1.	Pharmacokinetic prediction of selected compounds by QikProp® 3.2	108
5C.2.	Similarity of amino acid residues within the predicted active site and previously reported homology modelled ATD of AMPA receptor	109